PPH Legal Blog

The United States Food and Drug Administration has been investigating the drug Avandia for some time now. In early 2008, the FDA issued a warning letter to the drug’s manufacturer, GlaxoSmithKline, for postmarketing safety reporting failures.
The large manufacturer claims that any information that was withheld was done so by mistake. GlaxoSmithKline states that the missing […]

[Read more →]

Recent studies have shown that the drug known as Viagra has been successful in the treatment of primary pulmonary hypertension (PPH) in infants. Viagra, best known to treat erectile dysfunction in adult males, has proven to be effective as a pulmonary dilator.
According to doctors, Viagra works to loosen and relax the constricted arteries of a […]

[Read more →]

In early July, GeneraMedix was approved by the FDA for its Epoprostenol for injection 1.5mg drug. GeneraMedix’s Epoprostenol for injection 1.5mg is meant to be a long-term intravenous treatment for primary pulmonary hypertension (PPH).
PHH is caused by the thinning or narrowing of the blood vessels that supply the lungs. If left untreated, an individual’s blood […]

[Read more →]

After eight long weeks, the trial of Gallion and Cunningham ended in a mistrial due to a deadlocked jury. Their partner, Melbourne Mills, was acquitted before the jury became stuck on the charges against the former two. All three attorneys were accused of stealing $65 million dollars from the $200 million dollar lawsuit filed by […]

[Read more →]

Fen-phen, the diet drug wonder of the 1990’s, created many unfortunate and severe health complications in its users, including heart valve damage and primary pulmonary hypertension (PPH).  PPH is a rare and incurable disease which causes increased blood pressure and oxygen depletion in the lungs, forcing many patients to struggle for breath, especially with increased […]

[Read more →]